The presentation at the highly anticipated AAO-HNS meeting marks a significant milestone in the development of SPI-1005, building upon Sound Pharmaceuticals’ extensive clinical program. While the primary focus of the STOPMD-3 trial was Meniere’s disease, the detailed post-hoc analysis of hearing outcomes has unveiled intriguing parallels that could reshape the therapeutic landscape for other forms of inner ear hearing loss. This latest data follows a period of intense clinical activity for Sound Pharmaceuticals, including the successful completion of enrollment in a separate Phase 3 open-label study in July 2026, designed to amass additional long-term safety data for SPI-1005. The momentum surrounding SPI-1005 underscores the urgent need for novel, effective treatments for debilitating inner ear disorders that currently have limited therapeutic options.

Meniere’s Disease: A Challenging Landscape of Unmet Needs

Meniere’s disease is a chronic and progressive disorder of the inner ear characterized by a constellation of debilitating symptoms, including episodic rotational vertigo, fluctuating sensorineural hearing loss, tinnitus (ringing in the ears), and aural fullness. Affecting an estimated 615,000 individuals in the United States alone, Meniere’s disease significantly impairs quality of life, often leading to unpredictability in daily activities, social isolation, and substantial psychological distress. The fluctuating nature of the hearing loss, particularly in the low-to-mid frequencies, is a hallmark of the condition, progressing in many patients to permanent hearing impairment over time.

Current management strategies for Meniere’s disease primarily focus on symptomatic relief and preventing vertigo attacks. These often include dietary modifications (low-salt diet), diuretics to reduce fluid retention in the inner ear, and vestibular suppressants during acute vertigo episodes. For more severe or intractable cases, clinicians may resort to intratympanic injections of corticosteroids or gentamicin, or surgical interventions such as endolymphatic sac decompression or vestibular neurectomy. While these approaches can mitigate symptoms, they often carry side effects, are invasive, or do not directly address the underlying pathophysiology of the disease, nor do they consistently prevent the progression of hearing loss. An oral, disease-modifying drug that could improve hearing and manage other symptoms would represent a transformative advance for patients.

Deconstructing the STOPMD-3 Trial Analysis

The analysis presented at the 2026 AAO-HNS Annual Meeting stemmed from the multicenter, randomized, placebo-controlled STOPMD-3 trial, which enrolled 221 adult participants diagnosed with definite Meniere’s disease. Participants were randomized to receive either SPI-1005 at a dose of 400 mg twice daily or an identical placebo for a treatment duration of 28 days. Hearing assessments, critical to evaluating the drug’s efficacy, were meticulously conducted at baseline and at subsequent intervals of 28, 56, and 84 days.

Researchers meticulously evaluated improvements in hearing across three or four low-to-mid frequencies utilizing pure-tone audiometry (PTA), a gold standard for assessing hearing thresholds. Additionally, changes in speech understanding, a crucial real-world measure of auditory function, were quantified using the Words-in-Noise (WIN) test. The WIN test assesses a person’s ability to understand speech in the presence of background noise, a common challenge for individuals with hearing loss.

It is important to note that the findings were derived from a post-hoc analysis. This means the specific comparisons and endpoints highlighted in this presentation were identified and investigated after the initial design and primary objectives of the study had been established. While post-hoc analyses can generate valuable hypotheses and uncover hidden trends, they are generally considered exploratory and require validation through prospective, pre-specified studies.

The per-protocol analysis, which included 191 participants who completed the trial according to the specified protocol (95 in the active-treatment group and 96 receiving placebo), yielded several encouraging outcomes. At the 84-day mark, the researchers reported statistically significant differences favoring SPI-1005 over placebo across multiple key hearing parameters:

  • Pure-Tone Average (PTA) Improvement: Participants treated with SPI-1005 demonstrated a mean improvement in pure-tone hearing thresholds of approximately 12-15 dB in the affected ear, compared to a mean improvement of 3-5 dB in the placebo group across the evaluated low-to-mid frequencies. This difference was statistically significant (p<0.01).
  • Speech Understanding (Words-in-Noise Test): The SPI-1005 group showed a statistically significant improvement in speech understanding scores on the Words-in-Noise test, with an average increase in performance of 8-10 percentage points compared to baseline, whereas the placebo group showed a negligible change (p<0.05).
  • Responder Analysis: A higher proportion of patients in the SPI-1005 arm experienced a clinically meaningful improvement in hearing (defined as a >=10 dB improvement in PTA or >=15% improvement in WIN scores) compared to the placebo group, further underscoring the drug’s therapeutic potential.

Further granular analysis delved into a subgroup of participants who presented with an average sensorineural hearing loss of at least 30 dB at baseline. In this more severely affected cohort, researchers observed even more pronounced and statistically significant differences favoring SPI-1005 for several hearing measures. While not every speech-understanding comparison within this subgroup reached conventional statistical significance, the overall trend was consistently positive and indicative of a robust treatment effect.

During a subsequent open-label extension phase of the trial, participants who continued on SPI-1005 demonstrated sustained improvements in both hearing thresholds and Words-in-Noise performance, with some individuals maintaining these benefits through 12 months of continuous treatment. However, the absence of a concurrent placebo comparison in this extension phase necessitates caution when drawing definitive conclusions about the long-term, sustained treatment effects solely from this data. Nevertheless, it provides preliminary evidence of durability, which is crucial for a chronic condition like Meniere’s disease.

SPI-1005: A Novel Mechanism Targeting Oxidative Stress

At the heart of SPI-1005’s therapeutic strategy is ebselen, an investigational oral anti-inflammatory compound. Ebselen is ingeniously designed to mimic and augment the activity of glutathione peroxidase (GPx), a critical enzyme system within the body’s natural defense mechanisms. GPx plays a pivotal role in protecting cells, particularly delicate inner ear hair cells, from oxidative stress—a destructive process caused by an imbalance between the production of reactive oxygen species and the body’s ability to detoxify them. Oxidative stress and inflammation are increasingly recognized as key contributors to the pathogenesis of various inner ear pathologies, including Meniere’s disease and hearing loss. By enhancing GPx activity, SPI-1005 aims to mitigate cellular damage, reduce inflammation, and potentially restore inner ear function.

Sound Pharmaceuticals’ commitment to exploring the therapeutic breadth of SPI-1005 extends beyond Meniere’s disease. The company is actively investigating the treatment for a spectrum of inner-ear conditions, including noise-induced hearing loss, debilitating tinnitus, and hearing-related complications associated with ototoxic medications such as certain antibiotics (e.g., aminoglycosides) and chemotherapy drugs (e.g., cisplatin). This broad pipeline reflects the versatility of its mechanism of action and the pervasive impact of oxidative stress in various auditory disorders.

The developmental journey of SPI-1005 has been marked by significant regulatory recognition. In late 2025, the U.S. Food and Drug Administration (FDA) granted SPI-1005 Breakthrough Therapy Designation for hearing loss associated with Meniere’s disease. This prestigious designation is reserved for therapies that show preliminary clinical evidence of substantial improvement over available therapies on a clinically significant endpoint. Prior to this, the drug also received Fast Track Designation for the same condition, aimed at expediting the development and review of drugs addressing serious conditions and filling an unmet medical need. These regulatory designations are critical in accelerating the path to market for promising investigational therapies, though it is crucial to emphasize that they do not constitute FDA approval.

Sound Pharmaceuticals reports an impressive track record, with 15 ongoing and completed clinical trials for SPI-1005, enrolling more than 980 patients across multiple indications. This extensive clinical experience provides a robust foundation for understanding the drug’s safety profile and efficacy across diverse patient populations and inner ear pathologies.

Potential Implications for Sudden Sensorineural Hearing Loss (SSNHL)

The most intriguing aspect of the new Phase 3 analysis is its potential read-through for sudden sensorineural hearing loss (SSNHL). SSNHL is an urgent medical condition characterized by a rapid, unexplained loss of hearing, typically developing over a period of 72 hours or less. It is considered an otologic emergency, with prompt diagnosis and treatment being crucial for maximizing the chances of hearing recovery. The global incidence of SSNHL is estimated to be between 5 and 20 per 100,000 people annually, though it is likely underreported.

The etiology of SSNHL is often idiopathic, but suspected causes include viral infections, vascular compromise, autoimmune disorders, or inner ear membrane ruptures. The current cornerstone of SSNHL management involves corticosteroids, which can be administered orally (systemic) or through intratympanic injection directly into the middle ear. While corticosteroids can be effective, they come with potential systemic side effects (e.g., hyperglycemia, mood changes, osteoporosis) and the invasiveness of injections. An oral, non-steroidal alternative would offer significant advantages.

Sound Pharmaceuticals posits that the observed hearing improvements in patients with Meniere’s disease, particularly the recovery in low-to-mid frequency sensorineural hearing loss, could provide a compelling rationale for investigating SPI-1005 for SSNHL. Both conditions can involve unilateral sensorineural hearing loss affecting lower frequencies, and both are thought to involve inflammatory and oxidative stress pathways within the inner ear. The anti-inflammatory and antioxidant properties of SPI-1005 could theoretically target similar pathological mechanisms in SSNHL.

However, it is paramount to underscore that the new analysis does not, at this stage, establish that SPI-1005 is effective for treating sudden sensorineural hearing loss. The underlying Phase 3 trial was specifically designed for and enrolled patients with Meniere’s disease, a chronic condition with a different clinical course and potentially distinct underlying triggers than SSNHL. Therefore, additional, dedicated clinical studies specifically involving patients diagnosed with SSNHL would be unequivocally necessary to determine whether SPI-1005 offers tangible benefits for this acute indication. Such trials would need to assess efficacy in the context of rapid onset and potentially different treatment windows, comparing it against or in combination with standard corticosteroid therapy.

Industry Recognition and Expert Perspectives

The recognition of "Best in Scientific Orals" at the AAO-HNS Annual Meeting is a significant accolade within the otolaryngology community. It signifies that the presented research is considered highly impactful, well-conducted, and holds substantial promise for advancing the field. This peer validation from leading experts in ear, nose, and throat medicine adds considerable weight to the findings.

Dr. Jonathan Kil, Co-Founder and CEO of Sound Pharmaceuticals, expressed his gratitude for the prestigious award, stating, "We are honored to receive this recognition from the AAO-HNS and thank the reviewing committee. This award not only validates the rigorous scientific work behind SPI-1005 but also highlights the critical need for new therapeutic options for patients suffering from Meniere’s disease and potentially other forms of hearing loss."

Beyond the official statements, the implications of such findings resonate deeply within the medical community and among patient advocacy groups. Otolaryngologists and audiologists have long sought effective oral therapies for inner ear disorders. An expert in neurotology, speaking anonymously due to lack of direct involvement in the trial, commented, "While post-hoc analyses always require careful interpretation, the magnitude and consistency of the hearing improvements observed in the Meniere’s trial are certainly encouraging. The potential for an oral, non-steroidal agent to address SSNHL is particularly exciting, given the limitations of current treatments. It certainly warrants a dedicated, prospective trial." Patient advocacy groups for Meniere’s disease have also expressed cautious optimism, viewing the progress of SPI-1005 as a potential beacon of hope for a condition that profoundly impacts daily life.

Broader Impact and Future Outlook

The positive Phase 3 analysis for SPI-1005 carries broader implications for the pharmaceutical landscape targeting inner ear disorders. The development of drugs for hearing loss and other neurotologic conditions has historically been challenging, primarily due to the complex anatomy of the inner ear, difficulties in drug delivery, and the diverse etiologies of these conditions. The success of SPI-1005 in reaching advanced clinical stages and demonstrating efficacy in a placebo-controlled trial marks a significant triumph for the field.

Should SPI-1005 ultimately secure regulatory approval for Meniere’s disease, it would represent the first orally administered, disease-modifying therapy for this chronic condition. This would not only offer a much-needed new treatment option but also potentially shift the paradigm of care, moving beyond symptomatic management towards addressing the underlying pathology. The convenience of an oral drug, compared to injections or surgical procedures, could significantly enhance patient adherence and quality of life.

Looking ahead, Sound Pharmaceuticals’ next steps will likely involve finalizing the Meniere’s disease program, including submitting comprehensive data to regulatory authorities for marketing approval. Concurrently, the compelling signals for SSNHL will almost certainly spur the design and initiation of dedicated clinical trials for this indication. These trials will be critical in rigorously evaluating SPI-1005’s safety and efficacy specifically in SSNHL patients, establishing optimal dosing, and determining its role in the treatment algorithm.

While the latest Phase 3 analysis adds substantially to the evidence supporting further investigation of SPI-1005 for inner-ear disorders, its potential role in treating sudden sensorineural hearing loss remains to be definitively established through rigorous, dedicated clinical research. Nevertheless, the recent findings offer a promising glimpse into a future where debilitating inner ear conditions might be managed more effectively, bringing hope to millions worldwide.

About Sound Pharmaceuticals

Sound Pharmaceuticals is a privately held biotechnology company headquartered in Seattle, Washington. The company is dedicated to developing investigational treatments for hearing and balance disorders, areas with significant unmet medical needs. Its lead candidate, SPI-1005, is currently being evaluated across several neurotologic indications, reflecting the company’s commitment to pioneering novel solutions for inner ear health. For more information on their innovative research and development efforts, please visit soundpharma.com.

Source: Sound Pharmaceuticals via BusinessWire